People · Operator
Named in public records as an officer, director or promoter · active 2025–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ensho Therapeutics, Inc. | — | Biotechnology | Series B | $47.9M | $73.2M | 2025 |
Carlos Solorzano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carlos Solorzano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Whitney | 1 | 2 |
| Eric Pham | 1 | 2 |
| Arash Rassoulpour | 1 | 1 |
| Neena Bitritto-Garg | 1 | 1 |
| Emily Weng | 1 | 1 |
| Matthew McKevitt | 1 | 1 |
| Bittoo Kanwar | 1 | 1 |
| Danielle Andrew Fry | 1 | 1 |
| Matthew Andrew McKevitt | 1 | 1 |
| James Andrew Whitney | 1 | 1 |
| Danielle Fry | 1 | 1 |
| Emily Andrew Weng | 1 | 1 |
| Gerhard Hagn | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.